2. Search Result
Search Result
Results for "

LPS-induced acute lung injury

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

12

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N3006
    Sakuranetin
    Maximum Cited Publications
    8 Publications Verification

    		 Fungal Infection Inflammation/Immunology
    Sakuranetin is a cherry flavonoid phytoalexin, shows strong antifungal activity . Sakuranetin has anti-inflammatory and antioxidative activities. Sakuranetin ameliorates LPS-induced acute lung injury .
    Sakuranetin
  • HY-N0212
    Peimine
    4 Publications Verification

    Verticine; Dihydroisoimperialine

    		 Apoptosis Interleukin Related TNF Receptor p38 MAPK NF-κB Inflammation/Immunology Cancer
    Peimine (Verticine; Dihydroisoimperialine) is an orally active natural product. Peimine has anti-inflammatory, analgesic and cough relieving effects. Peimine can be used in cancer and inflammation related research .
    Peimine
  • HY-N0632
    Esculentoside A
    2 Publications Verification

    		 COX NF-κB Inflammation/Immunology
    Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta . Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models , has selective inhibitory activity towards cyclooxygenase-2 (COX-2) . Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways .
    Esculentoside A
  • HY-N0526
    2"-O-Galloylhyperin
    2 Publications Verification

    		 Sirtuin Keap1-Nrf2 NF-κB ERK p38 MAPK JNK TSH Receptor Reactive Oxygen Species (ROS) SOD Neurological Disease Inflammation/Immunology
    2''-O-Galloylhyperin is an active natural compound with anti‑inflammatory, antioxidant, anti‑adipogenic, antifibrotic, and cytostatic activities. 2''-O-Galloylhyperin upregulates SIRT1/Nrf2 signaling, inhibits NF-κB and MAPK (ERK1/2, p38, JNK) phosphorylation, suppresses TSHR activation, reduces ROS accumulation, and enhances SOD and GSH-Px activities. 2''-O-Galloylhyperin protects against LPS-induced tissue injury, enhances survival, and inhibits adipogenesis and fibrosis. 2"-O-Galloylhyperin can be used for the research of sepsis, acute lung injury, and thyroid eye disease .
    2
  • HY-128598
    MD2-TLR4-IN-1
    1 Publications Verification

    		 Toll-like Receptor (TLR) NF-κB Inflammation/Immunology Cancer
    MD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex antagonist. MD2-TLR4-IN-1 inhibits Lipopolysaccharides (HY-D1056) (LPS)-induced expression of TNF-α and IL-6 in macrophages with IC50 values of 0.89 μM and 0.53 μM, respectively. MD2-TLR4-IN-1 can be used for the study of acute lung injury (ALI) .
    MD2-TLR4-IN-1
  • HY-P99008
    Atibuclimab
    2 Publications Verification

    IC14

    		 Toll-like Receptor (TLR) Infection Neurological Disease Inflammation/Immunology
    Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
    Atibuclimab
  • HY-125516
    MCTR3

    		Endogenous Metabolite Others Inflammation/Immunology
    MCTR3 is a potent cytokine of pro-resolving mediating maresin conjugates in tissue regeneration (MCTR), which reduces the inflammatory response and promotes the tissue regeneration. MCTR3 exhibits potency in ameliorating LPS-induced acute lung injury and arthritis .
    MCTR3
  • HY-178136
    MyD88-IN-3

    		Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB JNK Infection Inflammation/Immunology
    MyD88-IN-3 is an orally active, selective MyD88 Inhibitor. MyD88-IN-3 specifically targets the TIR domain of MyD88 (KD = 28.5 μM), thereby preventing MyD88 self-polymerization and interaction with TLRs, which suppresses the activation of MAPK and NF-κB pathways. MyD88-IN-3 demonstrates significant anti-inflammatory efficacy and effectively mitigates Acute Lung Injury (ALI) symptoms in CLP (cecal ligation and puncture) and Lipopolysaccharides (HY-D1056) (LPS)-induced ALI models. MyD88-IN-3 can be used for the study of ALI .
    MyD88-IN-3
  • HY-106377
    BIO-11006

    		MARCKS Inflammation/Immunology
    BIO-11006 is a peptide that inhibits the function of the MARCKS protein. BIO-11006 attenuates LPS-induced neutrophil influx into the lungs, NF-κB activation, and expression of the proinflammatory cytokines KC and TNF-α. BIO-11006 also reverses disease progression in an LPS-induced mouse lung injury model. BIO-11006 is indicated for research on acute lung injury/acute respiratory distress syndrome (ALI/ARDS) .
    BIO-11006
  • HY-150055
    iNOs-IN-3

    		NO Synthase Inflammation/Immunology
    iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 µM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research .
    iNOs-IN-3
  • HY-160876
    BC-1901S

    		Keap1-Nrf2 E1/E2/E3 Enzyme Inflammation/Immunology
    BC-1901S is a proteasome-independent NRF2 activator and stabilizer. BC-1901S binds to DCAF1 (E3 ligase subunit) and disrupts NRF2/DCAF1 interaction, and activates NRF2 by inhibiting NRF2 ubiquitination in a KEAP1-independent manner. BC-1901S shows anti-inflammatory effect in a murine model of LPS-induced acute lung injury .
    BC-1901S
  • HY-N3006R
    Sakuranetin (Standard)

    		Reference Standards Fungal Infection Inflammation/Immunology
    Sakuranetin is a cherry flavonoid phytoalexin, shows strong antifungal activity . Sakuranetin has anti-inflammatory and antioxidative activities. Sakuranetin ameliorates LPS-induced acute lung injury .
    Sakuranetin (Standard)
  • HY-N12042
    Taxamairin B

    		TNF Receptor PI3K Reactive Oxygen Species (ROS) Interleukin Related Inflammation/Immunology
    Taxamairin B is a potent anti-inflammatory agent. Taxamairin B decreases proinflammatory cytokines (TNF-α, IL-1β and IL-6) expression and the production of NO and ROS in LPS-induced RAW264.7 cells. Taxamairin B exhibits significant protective effects in LPS-induced acute lung injury in mice .
    Taxamairin B
  • HY-N0632R
    Esculentoside A (Standard)

    		Reference Standards COX NF-κB Inflammation/Immunology
    Esculentoside A (Standard) is the analytical standard of Esculentoside A. This product is intended for research and analytical applications. Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta . Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models , has selective inhibitory activity towards cyclooxygenase-2 (COX-2) . Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways .
    Esculentoside A (Standard)
  • HY-N1546
    Protoplumericin A

    		Others Inflammation/Immunology
    Protoplumericin A is a bioactive ingredient of Plumeria obtusa L. attenuates. Protoplumericin A mitigated lipopolysaccharide (LPS) -induced acute lung injury in mice. Protoplumericin A can be used to study the LPS-induced anti-inflammatory effect .
    Protoplumericin A
  • HY-N0212R
    Peimine (Standard)

    Verticine (Standard); Dihydroisoimperialine (Standard)

    		 Reference Standards Apoptosis Interleukin Related TNF Receptor p38 MAPK NF-κB Inflammation/Immunology Cancer
    Peimine (Standard) is the analytical standard of Peimine. This product is intended for research and analytical applications. Peimine (Verticine; Dihydroisoimperialine) is an orally active natural product. Peimine has anti-inflammatory, analgesic and cough relieving effects. Peimine can be used in cancer and inflammation related research .
    Peimine (Standard)
  • HY-148552
    Anti-inflammatory agent 35
    1 Publications Verification

    		 p38 MAPK ERK NF-κB Interleukin Related TNF Receptor Inflammation/Immunology
    Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue with anti-inflammatory activity. Anti-inflammatory agent 35 blocks mitogen-activated protein kinase (MAPK) signaling and p65 nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits yellow neutrophil infiltration and pro-inflammatory cytokine production. Anti-inflammatory agent 35 significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI) in vivo .
    Anti-inflammatory agent 35
  • HY-149485
    JNK2-IN-1

    		JNK Inflammation/Immunology
    JNK2-IN-1 (Compound J27) is a JNK2 inhibitor (Kds: 79.2 μM). JNK2-IN-1 has anti-inflammatory activity. JNK2-IN-1 decreases the release of TNF-α and IL-6 through inhibiting the activation of NF-κB/MAPK pathway. JNK2-IN-1 alleviates the symptoms of LPS-induced acute lung injury (ALI) and sepsis .
    JNK2-IN-1
  • HY-168009
    NLRP3-IN-45

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-45 (D6) is an inhibitor of NLRP3 inflammasome activation, inhibiting the activity of IL-1β (IC50=41.79 nM). NLRP3-IN-45 exerts its effects without affecting the initial stage of NLRP3 inflammasome activation. NLRP3-IN-45 specifically inhibits the activation of NLRP3 inflammasome in the LPS-induced acute lung injury (ALI) mouse model .
    NLRP3-IN-45
  • HY-162317
    AMPK-IN-5

    		JAK p38 MAPK Infection
    AMPK-IN-5 (compound 7m) is a Osthole (HY-N0054) derivative, and blocks MAPK signal transduction by inhibiting the phosphorylation of JNK and p38, thereby inhibiting the release of inflammatory cytokines. AMPK-IN-5 reduce DSS-induced ulcerative colitis and LPS (HY-D1056)-induced acute lung injury .
    AMPK-IN-5
  • HY-N0526R
    2"-O-Galloylhyperin (Standard)

    		Reference Standards Sirtuin Keap1-Nrf2 NF-κB ERK p38 MAPK JNK TSH Receptor Reactive Oxygen Species (ROS) SOD Neurological Disease Inflammation/Immunology
    2"-O-Galloylhyperin (Standard) is the analytical standard of 2"-O-Galloylhyperin (HY-N0526). This product is intended for research and analytical applications. 2''-O-Galloylhyperin is an active natural compound with anti‑inflammatory, antioxidant, anti‑adipogenic, antifibrotic, and cytostatic activities. 2''-O-Galloylhyperin upregulates SIRT1/Nrf2 signaling, inhibits NF-κB and MAPK (ERK1/2, p38, JNK) phosphorylation, suppresses TSHR activation, reduces ROS accumulation, and enhances SOD and GSH-Px activities. 2''-O-Galloylhyperin protects against LPS-induced tissue injury, enhances survival, and inhibits adipogenesis and fibrosis. 2"-O-Galloylhyperin can be used for the research of sepsis, acute lung injury, and thyroid eye disease .
    2
  • HY-P10469
    NBD-2

    		NF-κB Inflammation/Immunology Cancer
    NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the NF-κB signaling pathway. NBD-2 specifically inhibits the typical NF-κB signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to NF-κB signaling pathway, including autoimmune diseases, cancer, etc .
    NBD-2
  • HY-N17317
    Isostrictiniin

    ITN

    		 Keap1-Nrf2 Heme Oxygenase (HO) JNK ERK p38 MAPK NF-κB Interleukin Related Metabolic Disease Inflammation/Immunology
    Isostrictiniin (ITN) is a polyphenolic compound isolated from Nymphaea candida. It upregulates the expression of Nrf2 and HO-1, while downregulating the expression of Keap1. Isostrictiniin reduces the phosphorylation levels of JNK, ERK1/2, p38, IκBα, and NF-κB p65. Isostrictiniin decreases the levels of pro-inflammatory mediators (IL-1β, IL-6, TNF-α, PGE2). Isostrictiniin alleviates LPS-induced acute lung injury and exerts protective effects against acute alcoholic liver injury. Additionally, isostrictiniin exhibits anti-inflammatory, antioxidant, and anti-fibrotic activities.
    Isostrictiniin
  • HY-162316
    NF-κB-IN-15

    		NF-κB Inflammation/Immunology
    NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI) .
    NF-κB-IN-15
  • HY-184027
    IDO1/TDO-IN-12

    		Indoleamine 2,3-Dioxygenase (IDO) TNF Receptor Interleukin Related Inflammation/Immunology
    IDO1/TDO-IN-12 is an IDO1/TDO2 inhibitor with IC50 values of 0.825 and 4.04 μM, respectively. IDO1/TDO-IN-12 interacts with the ferrous heme cofactor in IDO1 as a non-competitive tryptophan inhibitor. IDO1/TDO-IN-12 inhibits nitric oxide production in LPS (HY-D1056)-stimulated immune cells. IDO1/TDO-IN-12 relieves pulmonary edema and lung injury in LPS-induced mouse models. IDO1/TDO-IN-12 can be used for the research of acute lung injury (ALI) .
    IDO1/TDO-IN-12
  • HY-N19847
    LYRM03

    		Drug Derivative Aminopeptidase Endogenous Metabolite Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) NF-κB p38 MAPK IKK NO Synthase COX Inflammation/Immunology Cancer
    LYRM03 is a derivative of Ubenimex (HY-B0134) and a Aminopeptidase N inhibitor. LYRM03 is isolated from Streptomyces HCCB10043. LYRM03 inhibits TLR4, MyD88, NLRP3, ASC, NF-κB and p38 MAPK, stabilizes IκB, and suppresses LPS-induced expression of iNOS and COX-2. LYRM03 reduces the levels of inflammatory cytokines and oxidative stress markers, and alleviates pulmonary edema. LYRM03 exhibits anticancer activity against breast cancer. LYRM03 has anti-inflammatory activity. LYRM03 can be used in the research of acute lung injury and breast cancer .
    LYRM03
  • HY-181812
    JNK2/MKK7 PPI-IN-1

    		JNK p38 MAPK Interleukin Related TNF Receptor Inflammation/Immunology
    JNK2/MKK7 PPI-IN-1 is an orally active JNK2 inhibitor with an IC50 of 0.99 μM and a Kd of 81.6 μM. JNK2/MKK7 PPI-IN-1 inhibits JNK2 kinase activity, disrupts JNK2-MKK7 protein-protein interaction, and reduces c-Jun phosphorylation. JNK2/MKK7 PPI-IN-1 inhibits LPS-induced overexpression of inflammatory cytokines IL-6 and TNF-α. JNK2/MKK7 PPI-IN-1 can be used for the research of acute lung injury .
    JNK2/MKK7 PPI-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: